Pacira(PCRX) Prnewswire·2025-02-27 10:45Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, related to its main product Exparel, was ruled invalid by the court, which raises concerns about the validity of other patents held by the company [1]. - The invalidation of the '495 patent could result in more generic competitors entering the market and increased litigation costs for Pacira [1]. Financial Impact - Following the announcement of the patent ruling, Pacira's stock price plummeted from 11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff applications set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2].